MedTrace Logo

Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention

NCT01609647 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2014-12-23

No results posted yet for this study

Summary

High platelet reactivity unit (PRU) after loading dose clopidogrel in patients undergoing percutaneous coronary intervention (PCI) is related to high risk of short and long term recurrent ischemic events including stent thrombosis.

The investigators hypothesize that additional loading of prasugrel in patients with high PRU after clopidogrel loading would be superior to additional loading of clopidogrel in reducing platelet reactivity and thereby result in lower risk of short term recurrent ischemic events.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Prasugrel

Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days

DRUG

Clopidogrel

Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days

Sponsors & Collaborators

  • Dong-A University

    lead OTHER

Principal Investigators

  • Moo Hyun Kim, MD · Director, Regional Clinical Trial Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01609647 on ClinicalTrials.gov